Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 61859 | 68448 |
| Total Cites | 2149 | 2304 |
| H-index | 18 | 18 |
| Hm-index | 7 | 7 |
| Number of Single Authored Papers | 6 | 6 |
| Total Cites to Single Authored Papers | 1 | 1 |
| Number of Single+First Authored Papers | 57 | 57 |
| Total Cites to Single+First Authored Papers | 27 | 27 |
| Number of Single+First+Last Authored Papers | 400 | 400 |
| Total Cites to Single+First+Last Authored Papers | 652 | 662 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1883 | 1987 |
| Ratio of Total Citations to Distinct Citing Papers | 1.14 | 1.16 |
| Self-Citation Percentage |
6.73%
|
|
If you find an error in your data, please contact us with your profile link: Contact Us
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 60957 | 65657 |
| Total Cites | 2293 | 2536 |
| H-index | 18 | 19 |
| Hm-index | 7 | 7 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 61 | 61 |
| Total Cites to Single+First Authored Papers | 43 | 45 |
| Number of Single+First+Last Authored Papers | 394 | 394 |
| Total Cites to Single+First+Last Authored Papers | 667 | 712 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2019 | 2167 |
| Ratio of Total Citations to Distinct Citing Papers | 1.14 | 1.17 |
| Self-Citation Percentage |
9.58%
|
|
If you find an error in your data, please contact us with your profile link: Contact Us
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 64280 | 67186 |
| Total Cites | 3283 | 3639 |
| H-index | 22 | 24 |
| Hm-index | 9 | 10 |
| Number of Single Authored Papers | 6 | 6 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 57 | 57 |
| Total Cites to Single+First Authored Papers | 66 | 67 |
| Number of Single+First+Last Authored Papers | 377 | 377 |
| Total Cites to Single+First+Last Authored Papers | 931 | 992 |
| Composite Score | 2 | 3 |
| Number of Distinct Citing Papers | 2874 | 3100 |
| Ratio of Total Citations to Distinct Citing Papers | 1.14 | 1.17 |
| Self-Citation Percentage |
9.78%
|
|
If you find an error in your data, please contact us with your profile link: Contact Us
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 65621 | 72959 |
| Total Cites | 2215 | 2459 |
| H-index | 19 | 19 |
| Hm-index | 7 | 8 |
| Number of Single Authored Papers | 6 | 6 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 57 | 57 |
| Total Cites to Single+First Authored Papers | 55 | 56 |
| Number of Single+First+Last Authored Papers | 362 | 362 |
| Total Cites to Single+First+Last Authored Papers | 608 | 639 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1946 | 2098 |
| Ratio of Total Citations to Distinct Citing Papers | 1.14 | 1.17 |
| Self-Citation Percentage |
9.92%
|
|
If you find an error in your data, please contact us with your profile link: Contact Us
Overall Rank
Rank in SubField 1
Publications
Citations
Related Profiles
Partner with Us
📢 Partner with us and reach a targeted audience of science enthusiasts and professionals through our platform.
Partner with Us
📢 Partner with us and reach a targeted audience of science enthusiasts and professionals through our platform.